FORWARD LOOKING STATEMENTS

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, statements regarding (i) plans and objectives of management for operations of Haemonetics Corporation (the “Company”), including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products, and plans or objectives related to the Complexity Reduction Initiative and the Operational Excellence Program, (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the share repurchase program, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's ability to implement the Complexity Reduction Initiative and the Operational Excellence Program as planned, on the anticipated timeline and at the anticipated cost, the Company’s ability to realize the estimated savings from the Operational Excellence Program and the Complexity Reduction Initiative, the impact of share repurchases on the Company's stock price and volatility, as well as the effect of short-term price fluctuations on the program’s effectiveness, technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards, product quality, market acceptance, regulatory uncertainties, including in the receipt or timing of regulatory approvals, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (“SEC”).

The Company does not undertake to update these forward-looking statements.

MANAGEMENT’S USE OF NON-GAAP MEASURES

This presentation contains financial measures which are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for our reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in our underlying businesses. We strongly encourage investors to review our financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

When used in this presentation organic revenue growth excludes the impact of currency fluctuation, product end-of-life activities and divestitures. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted net income and adjusted earnings per share exclude restructuring and turnaround costs, accelerated device depreciation and related costs, asset impairments, deal amortization expenses, costs related to compliance with the new European Union Medical Device Regulation, impacts of U.S. tax reform, certain legal and other expenses, gains and losses on asset dispositions and the tax impact of the excluded items. Free cash flow before restructuring and turnaround is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment and does not include net cash proceeds received upon the sale of the Company’s Braintree corporate headquarters. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.

A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included in the Company’s earnings release for the third quarter of fiscal 2020 dated February 4, 2020, which is available on the Company’s website at www.haemonetics.com.
Global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare.
Well-positioned to create long-term value

Our 5-year Turnaround plan

Fast growing, innovative company that outpaces the market

- Accelerate growth
  - NexSys PCS® / NexLynk DMS® roll-out
  - Accelerated growth in Hospital
  - Inorganic growth opportunities

- Transform
  - BU-centric, performance-driven culture
  - Lean, improved operating model
  - Complexity Reduction Initiative (CRI)

- Stabilize
  - Stabilize Blood Center
  - Rationalize portfolio

FY17 FY19 FY21
Long-term value creation strategy supported by multiple value drivers

Corporate Strategy

- Compete in winning segments and geographies
- Achieve leading position in each segment where we compete
- Deliver superior short-term and long-term operating performance (ROIC)

Value drivers

1. Plasma market
2. Hospital market
3. Operating Model
4. Innovation Agenda
5. Operational Excellence
6. Capital Allocation
FY19 revenue snapshot in the customer-centric business unit structure

### Plasma
- % Revenue OUS\(^1\): 7%
- % Disp. revenue\(^2\): 93%
- % NA disp. revenue (excluding solutions)\(^3\): 76%

### Blood Center
- % Revenue OUS\(^1\): 68%
- % Disp. revenue\(^2\): 92%

### Hospital
- % Revenue OUS\(^1\): 47%
- % Disp. revenue\(^2\): 71%
- % HM\(^4\) revenue: 43%

### Service
- % Revenue OUS\(^1\): 59%

1. Outside of the United States
2. Disposables revenue
3. North America (NA) disposables revenue excluding liquid solutions. North American disposables revenue excluding liquid solutions adjusted for the divestiture of the Union facility is 79%
4. Hemostasis Management/TEG

FY19 Revenue: $968M

© 2020 Haemonetics Corporation
Leading position in Plasma with modern, integrated technology solutions

<table>
<thead>
<tr>
<th>Business Model</th>
<th>Product Portfolio</th>
<th>Market Lifecycle</th>
<th>Market Position</th>
<th>Competition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasmapheresis</td>
<td>Capital/Disposables</td>
<td>NexSys PCS®/PCS®2</td>
<td>Growth</td>
<td>Fresenius Fenwal (Aurora), Other (OUS)</td>
</tr>
<tr>
<td>Software</td>
<td>Software Solutions</td>
<td>NexLynk DMS®</td>
<td>Developing</td>
<td>MAK, homegrown</td>
</tr>
</tbody>
</table>

NexLynk DMS®
Donor management software

NexSys PCS®
Collection device

Value-added software “apps”
Plasma market continues to show strong growth and HAE is prepared to support this opportunity

**Robust growth in plasma-derived therapeutics**

- ~8% Est '15-'23 CAGR¹
- ~756 Registered clinical trials²
- Indications
- Formulations
- Diagnosis rates

**Therapeutic alternatives viewed as early stage**

- Pre-clin. Recombinant IgG
- PII FcRn

**Increased production capacity**

- ~2X Historical fractionation capacity³
  - (45M → 90M liters)
- ~9% '13-'17 CAGR⁴
- ~12% '13-'17 CAGR⁴
  - # of US plasma centers

**HAE positioned to support growth**

- ~50% Increase in plasma collection disposables capacity
- NexSys platform enables increase in plasma collection

---

2. clinicaltrials.gov 8/10/18 ClinicalTrials “plasma derived” search return
NexSys platform improves customer identified tangible value drivers

**Plasma Yield**
- Increased Plasma yield by 18-26ml per donation on average through YES® Technology¹

**Productivity**
- ~20% improvement in door to door efficiency²
- Increased labor effectiveness
- Business Optimization support
- 10% reduction in cost to collect a liter of plasma³

**Quality and Compliance**
- >91% reduction in key quality events (overdraws, documentation errors)²
- Bi-directional, paperless workflow helps eliminate errors and enforces compliance

**Donor Experience**
- Reduced donation times
- Increased donor engagement and satisfaction
- Improved staff responsiveness

---

¹ Plasma yield enhancing solution; YES® Technology is available in the United States only
² In-market results from NexSys PCS/NexLynk DMS implementations baselined versus Haemonetics PCS®2 device use, non bi-directionally integrated with Haemonetics DMS
³ Estimated based on internal data
Leading positions within three synergistic Hospital markets with state-of-the-art product offering

- **Hemostasis Management**
  - Capital/Disposables
    - **Business Model**
    - **Product Portfolio**
      - TEG® 5000, TEG®6s & TEG Manager
    - **Market Lifecycle**
      - Developing
    - **Market Position**
      - 1
    - **Competition**
      - IL (ROTEM), Stago (HemaSonics)

- **Cell Salvage**
  - Capital/Disposables
    - **Business Model**
    - **Product Portfolio**
      - Cell Saver® Elite® +
    - **Market Lifecycle**
      - Mature
    - **Market Position**
      - 2
    - **Competition**
      - LivaNova, Fresenius, Medtronic

- **Transfusion Management**
  - Software Solutions
    - **Business Model**
    - **Product Portfolio**
      - SafeTrace Tx®, BloodTrack®
    - **Market Lifecycle**
      - Mature
    - **Market Position**
      - Developing
    - **Competition**
      - Cerner, Mediware, MSoft
Strong market opportunity
TEG reinforces Hospital as a growth driver

HAE’s Hospital Near-term Market Opportunity in our Core Markets

- **Cell Salvage**
  - Share of voice:
    - CV Surgery
    - Trauma
  - ~$200M

- **Hemostasis Management**
  - Standard of care and market growth
  - Attractive core markets:
    - Interventional Cardiology
    - CV Surgery
    - Trauma
  - Hospital growth platform
  - ~$1.0B

- **Transfusion Management**
  - Next generation BBIS
  - Smarter and safer BIMS
  - ~$300M

1. Annual disposables market only in core markets
2. HIMSS Logic Database, Internal Analysis & Calculations
3. Blood Bank Information System
4. Blood Inventory Management System

© 2020 Haemonetics Corporation
Three Blood Center portfolios that offer safe, reliable blood collection solutions

**Business Model**
- **Apheresis**: Capital/Disposables
- **Whole Blood**: Disposables
- **Software**: Software Solutions

**Product Portfolio**
- **Apheresis**: MCS+ Suite, ACP-215
- **Whole Blood**: Manual Blood Collections and Filtration
- **Software**: Eldorado Donor, SafeTrace, EdgeBlood, eDonor, Hemasphere, Surround

**Market Lifecycle**
- **Apheresis**: Mature
- **Whole Blood**: Mature
- **Software**: Mature

**Competition**
- Fresenius, Terumo
- Fresenius, Terumo, Macopharma
- MAK

© 2020 Haemonetics Corporation
Blood Center market remains challenging
Significant cash flow opportunity

**Market:**
- Decline in blood transfusion rates due to:
  - Less invasive surgeries
  - Improvements in BMP\(^1\)
  - Pharmaceuticals
- High-yield, multi-dose collections setting new standards and reducing revenues
- Tender-driven business creates pricing pressures (mostly OUS)

**HAE Opportunity:**
- Focus on profitability and cash flow
- Customized pricing strategies
- Complexity reduction through:
  - Standardized technology
  - Optimized product portfolio
  - Reduced commercial footprint
- Improvements in cost of goods sold
- Strategic resource allocation

---


© 2020 Haemonetics Corporation
Innovation Agenda supports long-term growth

<table>
<thead>
<tr>
<th>Plasma</th>
<th>Hospital</th>
<th>Blood Center</th>
</tr>
</thead>
</table>
| • Greater plasma collection  
  • Better donor engagement  
  • Improved safety | • Broader indications for TEG®  
  • Region specific innovation  
  • Integrated software solutions | • Safer donations & end products  
  • Customized donor collections  
  • Increased product yield |

VOC & Customer Engagements
Clinical & Real-world Evidence
Software & Digital Solutions
Our productivity programs reduce inefficiency and free up resources to fund growth investments.

<table>
<thead>
<tr>
<th>Complexity Reduction Program</th>
<th>Operational Excellence Program</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Timing</strong></td>
<td>FY18 – FY20</td>
</tr>
<tr>
<td><strong>Scope</strong></td>
<td>G&amp;A, productivity</td>
</tr>
<tr>
<td><strong>Gross Savings (target)</strong></td>
<td>$80M+</td>
</tr>
<tr>
<td><strong>Net Savings ¹ (target)</strong></td>
<td>Modest</td>
</tr>
<tr>
<td><strong>CAPEX</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>One-time program costs²</strong></td>
<td>$50 - $60M</td>
</tr>
</tbody>
</table>

¹. The amount of savings estimated to drop through to the bottom line by the end of the program.
². Include restructuring charges over the course of the program. These charges will be excluded from the adjusted results.
Capital allocation priorities support organic and inorganic value creation

1. Organic business needs (R&D, S&M, CAPEX)
2. Inorganic growth opportunities (including M&A)
3. Share repurchases to offset dilution
### Key accomplishments across our value drivers

<table>
<thead>
<tr>
<th>Category</th>
<th>Accomplishments</th>
</tr>
</thead>
</table>
| **Plasma**             | • Launched NexSys and converted 20%+ of plasma customers  
                         • Upgraded software and increased software market share up to 75%                                                                       |
| **Hospital**           | • Dedicated BU propelled growth from flat to double digits  
                         • Established segment teams & bought Intellectual Property for TEG                                                                        |
| **Operating Model**    | • Rationalized product portfolio and right-sized Blood Center go-to-market efforts  
                         • Expanded Plasma and TEG disposables production capacity by 50%                                                                       |
| **Innovation Agenda**  | • Developed medical, clinical and scientific expertise  
                         • Invested in data and analytics capabilities to drive digitalization                                                                      |
| **Operational Excellence** | • Fostered a collaborative, performance-driven culture focused on value creation  
                                  • Launched two distinct productivity programs targeting $160-170M in savings                                                          |
| **Capital Allocation** | • Refinanced and expanded debt facility and allocated capital for accelerated growth  
                         • Executed $435M¹ share repurchase (outstanding authorization is for $325M)                                                              |

1. Includes $260M and $175M of share repurchases under the share repurchase authorizations announced on February 6, 2018 and May 7, 2019 respectively.
### Turnaround progress: Sustaining Revenue growth coupled with stronger operating and financial leverage

<table>
<thead>
<tr>
<th></th>
<th>FY16</th>
<th>YTD FY20¹</th>
<th>FY21 LRP⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP</td>
<td>0%</td>
<td>4%</td>
<td></td>
</tr>
<tr>
<td>Organic²</td>
<td>1%</td>
<td>8%</td>
<td></td>
</tr>
<tr>
<td><strong>Operating Margin³</strong></td>
<td></td>
<td></td>
<td>~20% or 2x FY16 OI</td>
</tr>
<tr>
<td>GAAP</td>
<td>(5%)</td>
<td>10%</td>
<td></td>
</tr>
<tr>
<td>Adjusted</td>
<td>13%</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td><strong>EPS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP</td>
<td>($1.09)</td>
<td>$1.13</td>
<td></td>
</tr>
<tr>
<td>Adjusted</td>
<td>$1.63</td>
<td>$2.61</td>
<td></td>
</tr>
<tr>
<td><strong>CFO &amp; FCF</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFO</td>
<td>$122M</td>
<td>$112M</td>
<td>4x FY16 or ~$232M</td>
</tr>
<tr>
<td>FCF⁴</td>
<td>$58</td>
<td>$95M</td>
<td></td>
</tr>
</tbody>
</table>

2. Organic growth excludes the impact of currency fluctuation, product end-of-life decisions and divestitures. FY16 Organic revenue growth also excludes the impact of the 53rd week.
3. Operating Margin percentage is calculated as Operating Income/Loss divided by Revenue (as Reported); Adjusted Operating Margin percentage is calculated as Adjusted Operating Income divided by Revenue (as Reported).
4. Free cash flow before restructuring and turnaround costs